caa a22 4500 445802979 CHVBK 20180317145147.0 cr unu---uuuuu 170323e20110501xx s 000 0 eng 10.1007/s10337-011-1983-9 doi (NATIONALLICENCE)springer-10.1007/s10337-011-1983-9 LC-MS-MS Method for the Analysis of New Non-Imidazole Histamine H3 Receptor Antagonist 1-[3-(4- tert -Butylphenoxy)propyl]piperidine in Rat Serum—Application to Pharmacokinetic Studies [Elektronische Daten] [Malgorzata Szafarz, Joanna Szymura-Oleksiak, Dorota Lazewska, Katarzyna Kiec-Kononowicz] A sensitive and specific liquid chromatography electrospray ionisation-tandem mass spectrometry method for determination of new non-imidazole histamine H3 receptor antagonist 1-[3-(4-tert-butylphenoxy)propyl]piperidine (DL76) in rat serum has been developed and validated. Chromatography was performed on a XBridge™ C18 analytical column (2.1×30mm, 3.5µm, Waters, Ireland) with gradient elution using a mobile phase containing acetonitrile and water with an addition of 0.1% of formic acid. Detection was achieved by an Applied Biosystems MDS Sciex (Concord, Ontario, Canada) API 2000 triple quadrupole mass spectrometer. Electrospray ionization (ESI) was used for ion production. The limit of detection in the SRM mode was found to be 0.5ngmL−1. The limit of quantification was 1ngmL−1. The precision and accuracy for both intra- and inter-day determination of DL76 ranged from 1.65 to 15.09% and from 88.74 to 113.43%. The results of this analytical method validation allow to carry out pharmacokinetic studies in rats. The method was used for the pilot study of the pharmacokinetic behavior of DL76 in rats after intravenous administration. The Author(s), 2011 Column liquid chromatography nationallicence Tandem MS detection nationallicence DL76 compound nationallicence Histamine H3 receptor antagonist nationallicence Rats serum nationallicence Szafarz Malgorzata Department of Pharmacokinetics and Physical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland aut Szymura-Oleksiak Joanna Department of Pharmacokinetics and Physical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland aut Lazewska Dorota Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland aut Kiec-Kononowicz Katarzyna Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland aut Chromatographia Springer-Verlag 73/9-10(2011-05-01), 913-919 0009-5893 73:9-10<913 2011 73 10337 https://doi.org/10.1007/s10337-011-1983-9 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10337-011-1983-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Szafarz Malgorzata Department of Pharmacokinetics and Physical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland aut NATIONALLICENCE 700 1- Szymura-Oleksiak Joanna Department of Pharmacokinetics and Physical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland aut NATIONALLICENCE 700 1- Lazewska Dorota Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland aut NATIONALLICENCE 700 1- Kiec-Kononowicz Katarzyna Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland aut NATIONALLICENCE 773 0- Chromatographia Springer-Verlag 73/9-10(2011-05-01), 913-919 0009-5893 73:9-10<913 2011 73 10337 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer